Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NDI-225673
- Development stage
- Phase 1
- Lead developer
- Nimbus Salacia
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NDI-225673 is an oral, highly selective small molecule inhibitor of salt-inducible kinase 2 (SIK2) being developed by Nimbus Therapeutics (via its subsidiary Nimbus Salacia) for the treatment of inflammatory bowel disease (IBD) and other chronic inflammatory and autoimmune conditions. SIK2 is a key signaling node in myeloid cells that regulates proinflammatory gene expression. By selectively inhibiting SIK2, NDI-225673 suppresses the production of multiple proinflammatory cytokines (such as TNF-alpha, IL-23, and IL-6) while simultaneously upregulating pro-resolution and tissue repair factors (such as IL-10), thereby promoting mucosal healing. NDI-225673 is currently in Phase 1 clinical development.
02
Targets
SIK1 (Salt-inducible kinase 1)SIK2 (Salt inducible kinase 2)SIK3
Beyond the preview
Go deeper on NDI-225673.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NDI-225673.